US Stock MarketDetailed Quotes

PSTV Plus Therapeutics

Watchlist
  • 1.1500
  • -0.0100-0.86%
Close Dec 30 16:00 ET
  • 1.1090
  • -0.0410-3.57%
Post 20:01 ET
6.78MMarket Cap-0.49P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 17 06:33
    NEWS
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
    Tuesday, 17th December at 7:30 am
    Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation
    Both single-dose and multiple-dose expansion trials planned in 2025
    AUSTIN, Texas, Dec. 17...
    Jaguar8
    Jaguar8
    Dec 4 17:56
    NEWS TODAY
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
    Plus Therapeutics (PSTV) will present Phase 1 interim data for its ReSPECT-LM trial at the 2024 San Antonio Breast Cancer Symposium. The presentation will focus on Rhenium (186Re) Obisbemeda treatment for leptomeningeal metastases (LM) in breast cancer patients.
    The presentation, led by Dr. Andrew Brenner from the Unive...
    Jaguar8
    Jaguar8
    Dec 3 06:38
    NEWS
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
    Tuesday, 3rd December at 7:30 am
    AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group...
    Jaguar8
    Jaguar8
    Nov 22 06:45
    NEWS
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
    Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints
    CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases
    Assay demonstrated 2.8 times the diagnost...
    Jaguar8
    Jaguar8
    Oct 1 06:31
    NEWS
    $Plus Therapeutics (PSTV.US)$
    Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
    Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy
    Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy
    ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New Y...
    1
Read more
Heat List
US
Overall
Symbol
Price
% Chg

No Data